All Names: Idhifa,Enasidenib
Indications:Acute Myeloid Leukemia (AML)
Manufacturer:Celgene,USA
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
DOSAGE(服用剂量)
Select patients for the treatment of AML with IDHIFA based on the presence of IDH2 mutations in the blood or bone marrow.
Recommended Dosage
The recommended dosage of IDHIFA is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
Do not split or crush IDHIFA tablets. Administer IDHIFA tablets orally about the same time each day. If a dose of IDHIFA is vomited, missed, or not taken at the usual time, administer the dose as soon as possible on the same day, and return to the normal schedule the following day.
ADVERSE REACTIONS(不良反应)
Differentiation Syndrome
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6/spl-doc?hl=Enasideni
Enasidenibinformation
No information yet!!!